| Outcome Measures: |
Primary: MACE, Myocardial Infarction, Ischemic Stroke, Cardiovascular mortality, through study completion, an average of 1 year|Modified MACE, Myocardial Infarction, Ischemic Stroke, All-Cause mortality, through study completion, an average of 1 year|Hospitalization for Heart Failure (HHF) Hospitalization for Heart Failure (HHF), through study completion, an average of 1 year | Secondary: Myocardial Infarction (MI), through study completion, an average of 1 year|Stroke, through study completion, an average of 1 year|Cardiovascular Mortality, through study completion, an average of 1 year|All-cause mortality, through study completion, an average of 1 year|Coronary revascularization, through study completion, an average of 1 year | Other: CKD progression, Sustained decrease in eGFR, KRT (maintenance dialysis and kidney transplantation), kidney death \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Sustained decrease in eGFR, \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Kidney replacement therapy (KRT), \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Kidney death, \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Kidney failure, (sustained eGFR \<15 ml/min/1.73m2, maintenance dialysis and kidney transplant) \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Early kidney disease, Defined by change in eGFR in patients with baseline eGFR \> 60 \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Glycemic control, Defined by HbA1c change in patients with available baseline HbA1c, through study completion, an average of 1 year|Insulin initiation, through study completion, an average of 1 year|Weight loss or gain, Defined by weight change in patients with available baseline weight \* exploratory outcome, since no validated claim-based outcome definition is currently available, through study completion, an average of 1 year|Diabetic ketoacidosis, exposure of interest - SGLT-2i, through study completion, an average of 1 year|Bone fractures, exposure of interest - SGLT-2i, through study completion, an average of 1 year|Lower-limb amputations, exposure of interest - SGLT-2i, through study completion, an average of 1 year|Acute kidney injury, exposure of interest - all drug classes, through study completion, an average of 1 year|Urinary infections, exposure of interest - SGLT-2i, through study completion, an average of 1 year|Genital infections, exposure of interest - SGLT-2i, through study completion, an average of 1 year|Acute pancreatitis, exposure of interest - GLP1 RA, DPP4i, through study completion, an average of 1 year|Biliary events, exposure of interest - GLP1 RA, DPP4i, through study completion, an average of 1 year|Severe hypoglycemia, exposure of interest - SU, through study completion, an average of 1 year|Short-term retinopathy progression, exposure of interest - GLP1 RA \* exploratory outcomes, since no validated outcome definition is currently available, through study completion, an average of 1 year|Home time, Time spent out of hospital and skilled nursing facility, Time to Nursing Home Placement, through study completion, an average of 1 year|Medication persistence, Time to discontinuation, through study completion, an average of 1 year|Switching patterns, Treatment trajectories: patterns of use following initiation of treatment under study. To be illustrated using concentric circle diagrams or Sankey diagrams as appropriate., through study completion, an average of 1 year
|
